NIVOLUMAB



Opdivo


Indication:


Opdivo (Nivolumab) is used to treat certain types of cancers (skin, lung, and kidney cancer). It works by changing the action of your own immune system, directing it to attack cancer cells. Opdivo (Nivolumab) belongs to a class of drugs known as monoclonal antibodies.



Brand name:Opdivo

Active Ingeridents:Nivolumab

Company Name:Bristol-Myers Squibb

Package:Vial

Strength :40mg/4ml

Mechanism of action:


Opdivo (Nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models.


Dosage and Administration:


  • Opdivo (Nivolumab) is administered intraveniously (IV) into the vein over 60 minutes every 2 weeks.
  • The amount of Opdivo (Nivolumab) that you will receive depends on many factors, your general health or other health problems, and the type of cancer or condition being treated. Higher doses do not give a better response and may cause increased toxicity. Your doctor will determine your dose and schedule.
  • If you miss any appointments call your healthcare provider as soon as possible to reschedule your appointment.

Store:


Store at room temperature, away from heat, moisture, Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.

Side effects:


The following side effects are common (occurring in greater than 30%) for patients taking Opdivo ( Nivolumab):

  • Fatigue , Lymphocytopenia (low white blood cells), Low sodium, Shortness of breath, Musculoskeletal pain, Decreased appetite, Cough

  • These side effects are less common side effects (occurring in about 10-29%) of patients receiving Opdivo ( Nivolumab):

  • Nausea, Anemia, Constipation, Increased serum creatinine, Colitis, Low potassium, Low magnesium, High calcium, Vomiting, Weakness, Diarrhea, High potassium, Low calcium, Swelling, Fever, Rash, Abdominal pain, Increased serum AST, Thrombocytopenia, Increased serum alkaline phosphatase, Chest pain, Weight loss, Joint pain, Increased serum ALT, Itching, Pneumonia, Pain



Precaution:


Before starting Opdivo (Nivolumab) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).

Do not receive any kind of immunization or vaccination without your doctor's approval while taking Opdivo ( Nivolumab).


WARNING:


Opdivo (Nivolumab) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




Opdivo



Indication:


Opdivo (Nivolumab) is used to treat certain types of cancers (skin, lung, and kidney cancer). It works by changing the action of your own immune system, directing it to attack cancer cells. Opdivo (Nivolumab) belongs to a class of drugs known as monoclonal antibodies.



Brand name:Opdivo

Active Ingeridents:Nivolumab

Company Name:Bristol-Myers Squibb

Package:Vial

Strength :100mg/10ml

Mechanism of action:


Opdivo (Nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models.


Dosage and Administration:


  • Opdivo (Nivolumab) is administered intraveniously (IV) into the vein over 60 minutes every 2 weeks.

  • The amount of Opdivo (Nivolumab) that you will receive depends on many factors, your general health or other health problems, and the type of cancer or condition being treated. Higher doses do not give a better response and may cause increased toxicity. Your doctor will determine your dose and schedule.

  • If you miss any appointments call your healthcare provider as soon as possible to reschedule your appointment.

Store:


Store at room temperature, away from heat, moisture, Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.


Side effects:


Store at room temperature, away from heat, moisture, Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.

  • Fatigue , Lymphocytopenia (low white blood cells), Low sodium, Shortness of breath, Musculoskeletal pain, Decreased appetite, Cough

  • These side effects are less common side effects (occurring in about 10-29%) of patients receiving Opdivo ( Nivolumab):

  • Nausea, Anemia, Constipation, Increased serum creatinine, Colitis, Low potassium, Low magnesium, High calcium, Vomiting, Weakness, Diarrhea, High potassium, Low calcium, Swelling, Fever, Rash, Abdominal pain, Increased serum AST, Thrombocytopenia, Increased serum alkaline phosphatase, Chest pain, Weight loss, Joint pain, Increased serum ALT, Itching, Pneumonia, Pain





Precaution:


Before starting Opdivo ( Nivolumab) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).

Do not receive any kind of immunization or vaccination without your doctor's approval while taking Opdivo ( Nivolumab).


WARNING:


Opdivo (Nivolumab) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.